{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T03:40:26Z","timestamp":1699846826388},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":9697,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1980,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aminoglutethimide (AG) with Dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and\/or positive estrogen receptor. Objective tumor response (CR + PR) has been achieved in 13 of 26 patients. Responses were seen in soft tissue, bone, and pleura. Six of 26 patients had stable disease and seven of 26 patients had progressive disease. The median duration of response is 12.8 months. The median survival for the responders has not been reached. Non\u2010responding patients had a median survival of five months. Side effects were minimal, including mild lethargy, rash, fever, and weight gain. This regimen is well tolerated and can be used effectively in metastatic hormone\u2010receptor\u2010positive breast cancer.<\/jats:p>","DOI":"10.1002\/mpo.2950080307","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T15:04:24Z","timestamp":1171983864000},"page":"251-263","source":"Crossref","is-referenced-by-count":3,"title":["Aminoglutethimide in the management of metastatic breast cancer"],"prefix":"10.1002","volume":"8","author":[{"given":"Niramol","family":"Savaraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Troner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1962.01310050102016"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(68)80099-6"},{"key":"e_1_2_1_4_2","first-page":"259","article-title":"Endocrine treatment of breast cancer","volume":"1","author":"Forrest APM","year":"1965","journal-title":"Israel J Med Sci"},{"key":"e_1_2_1_5_2","first-page":"5","volume-title":"Endocrine Aspects of Breast Cancer","author":"Hellstrom J","year":"1958"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197112)28:6<1699::AID-CNCR2820280660>3.0.CO;2-G"},{"key":"e_1_2_1_7_2","first-page":"241","article-title":"Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast","volume":"133","author":"Fracchia AA","year":"1971","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_1_8_2","first-page":"747","article-title":"The results of adrenalectomy in advanced breast cancer in 500 consecutive patients","volume":"125","author":"Fracchia AA","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_1_9_2","first-page":"825","article-title":"Bilateral adrenalectomy for advanced breast cancer. A 21 year experience","volume":"77","author":"Silverstein MJ","year":"1975","journal-title":"Surgery"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196009\/10)13:5<1074::AID-CNCR2820130531>3.0.CO;2-9"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5351.210"},{"key":"e_1_2_1_12_2","first-page":"165","volume-title":"Endocrine Therapy in Malignant Disease","author":"Stoll BA","year":"1972"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195901\/02)12:1<93::AID-CNCR2820120115>3.0.CO;2-I"},{"key":"e_1_2_1_14_2","first-page":"1140","article-title":"Cortisone treatment of metastatic breast cancer","volume":"15","author":"Nissen\u2010Meyer R","year":"1959","journal-title":"Acta Un Int Cancer"},{"key":"e_1_2_1_15_2","first-page":"51","article-title":"Cortisone\u2010induced remissions in women with metastatic mammary cancer","volume":"1","author":"West CD","year":"1954","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197307)32:1<31::AID-CNCR2820320104>3.0.CO;2-5"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.1974.03240120029015","article-title":"Successful medical adrenalectomy with Aminoglutethimide: Role of altered drug metabolism","volume":"230","author":"Santen RJ","year":"1974","journal-title":"JAMA"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197706)39:6<2948::AID-CNCR2820390681>3.0.CO;2-9"},{"key":"e_1_2_1_20_2","first-page":"376A","article-title":"Treatment of advance breast cancer with Aminoglutethimide: An 8 year experience","volume":"24","author":"Gale KE","year":"1976","journal-title":"Clin Res"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92759-9"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197702)39:2<542::AID-CNCR2820390224>3.0.CO;2-R"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197805000-00004"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197906)43:6<2207::AID-CNCR2820430608>3.0.CO;2-1"},{"key":"e_1_2_1_25_2","unstructured":"ValensteinSL VoightW VogelCL ThompsonS TempleW: The reliability of estrogen receptor in predicting hormonal responsiveness in the treatment of metastatic breast cancer. Experience of the Comprehensive Cancer Center for the State of Florida Florida Medical Association Journal (in press)."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-45-4-739"},{"key":"e_1_2_1_27_2","first-page":"356","article-title":"The tumor lysis syndrome: A consequence of successful chemotherapy","volume":"18","author":"Muranson DS","year":"1977","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-36-2-207"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-45-3-480"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-45-3-469"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950080307","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950080307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T03:11:51Z","timestamp":1699845111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950080307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1980,1]]}},"alternative-id":["10.1002\/mpo.2950080307"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950080307","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,1]]}}}